News | News By Subject | News by Disease News By Date | Search News

Lymphoma (T-cell) News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Solid Lymphoma Data Points To Larger Potential For Epizyme (EPZM), Says Citi     11/21/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
FDA Green Lights Spectrum Pharmaceuticals, Inc. (SPPI)'s Beleodag To Treat Rare Form Of Lymphoma     7/3/2014
Allos Therapeutics, Inc. (ALTH) Announces Final Results from Pivotal PROPEL Trial of Pralatrexate in Patients with Peripheral T-cell Lymphoma; Company Plans to Submit New Drug Application to FDA in First Half of 2009     2/4/2009
Gloucester Pharmaceuticals, Inc. Reports Positive Interim Phase II Data On Romidepsin For Peripheral T-Cell Lymphoma At The 2006 American Society of Hematology Annual Meeting     12/12/2006
Genmab A/S (GNMSF.PK) Obtains Special Protocol Assessment Agreement For HuMax-CD4(TM) Pivotal Study     4/20/2005
Ligand Pharmaceuticals Inc. (LGND) Exercises First Option To Buy Down ONTAK Royalties     1/7/2005
Myriad Genetics, Inc. (MYGN) Submits IND On Cancer Drug Candidate     12/28/2004
Gloucester Pharmaceuticals, Inc. Receives Fast Track Designation For FK228 In Cutaneous T-Cell Lymphoma     10/12/2004
Biocryst Pharmaceuticals (BCRX) Receives Orphan Drug Designation For BCX-1777 In Two Additional Cancer Indications     8/24/2004

News from Around the Web

Press Releases
Clinigen And Onxeo Initiate Managed Access Programme For Belinostat In Europe For Patients With Peripheral T-Cell Lymphoma (PTCL)     4/25/2017
Onxeo Announces Development Of Beleodaq Oral Formulation Opening New Opportunities For Its HDAC Inhibitor     6/2/2016
Pharma Mar Will Be Present At The 2016 Annual AACR Congress With The Latest Novelties In Its Compounds Of Marine Origin In Solid And Hematological Tumors     4/14/2016
Solasia Pharma K.K. Initiates Phase 2 Study Of Darinaparsin (SP-02) For Peripheral T-Cell Lymphoma     3/28/2016
miRagen Initiates First Clinical Trial For MRG-106 In Lymphoma Patients     3/2/2016
Adaptive Biotech And Collaborators Demonstrate Value Of Immunosequencing For Diagnosis Of Cutaneous T-Cell Lymphoma     10/8/2015
Kura Oncology Initiates Phase II Study Of Tipifarnib In Peripheral T-Cell Lymphoma     9/30/2015
Seattle Genetics (SGEN) Completes Enrollment In Phase III ALCANZA Clinical Trial Evaluating ADCETRIS (Brentuximab Vedotin) In CD30-Expressing Cutaneous T-Cell Lymphoma (CTCL)     9/9/2015
HUYA Bioscience International Announces Epigenetic Breast Cancer Program     9/3/2015
HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting     8/27/2015
PharmaMar Announces License Agreement With Specialised Therapeutics Australia Pty For APLIDIN (plitidepsin) In Oncology     8/20/2015
Soligenix (SNGX) Announces Recent Highlights and Second Quarter 2015 Financial Results     8/12/2015
Soligenix (SNGX) Receives Orphan Drug Designation From The European Commission (EC) For SGX301 As A Treatment For Cutaneous T-Cell Lymphoma     8/4/2015
Soligenix (SNGX) Enters Into A $10 Million Equity Purchase Agreement     8/3/2015
ProNAi Therapeutics, Inc. Initiates Phase 2 Trial Of PNT2258 In Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)     1/7/2015